Patient A.D., a group O Rh-negative female who had received RhIg at 28 weeks gestation had a weak anti-D when a type and screen was done prior to performance of a Cesarean section (C-section). A mini-panel of selected red cells confirmed the presence of anti-D and excluded other antibodies. The laboratory decided that the anti-D was likely passive and consistent with RhIG administration.
A group O Rh-positive child was delivered by C-section. The newborn had a weakly positive DAT but was healthy and required no treatment.
A rosette test to screen for FMH was negative and Patient A.D. was injected with 1500 IU (300 µg) of RhIG within 72 hours of delivery.
